The stock of Diebold Nixdorf, Incorporated (NYSE:DBD) is now priced at $8.15 and the shares are -0.53 points down or -6.11% lower compared to its previous closing price of $8.68. DBD shares have a float of 71.38 million and although its performance was -1.57% over the week, it’s one to watch. Analysts have given the DBD stock a yearly average price target of $12.5 per share. It means the stock’s upside potential is 53.37% with the DBD share price recently placing at $8.035 to $8.7. However, some brokerage firms have priced the stock below the average, including one that has called $10.
The shorts are running away from the Diebold Nixdorf, Incorporated stock, with the latest data on short interest released on July 31, 2020, showing that short interest numbers in the DBD shares have declined. Short interest in the stock represents just 14.57% of its float, but the volume has dropped by 0.
In the last trading session, Diebold Nixdorf, Incorporated (NYSE:DBD) dropped by -$0.13 over the week and gained $2.25 on its 20-day. The stock’s high in the recent session is lower when compared to its 52-week high of $13.99. The stock recorded its established 52-week high on 09/11/19.
Since 04/03/20, the stock has traded to a low of $2.8 at 191.07%, an encouraging piece of data likely to interest most investors out to exploit the stock’s recent surge. The stock has a beta allocation of 3.31. Being above 1 means that the stock’s volatility is higher than the market and traders are keenly watching it.
Looking at current readings, Diebold Nixdorf, Incorporated’s two-week RSI is 61.64. This suggests that the stock is neutral at the moment and that DBD shares’ price movement remains stable. The stochastic readings are equally revealing at 84.76% meaning the DBD share price is currently in oversold territory.
The technical chart shows that the DBD stock will likely settle at between $8.55 and $8.96 per share. However, if the stock dips below $7.89, then its market would become much weaker. Any downside could see the stock price sliding to levels as low as $7.63.
Currently, the stock is trading in the green of MACD, with a reading of 0.14. Investors always pay attention to any move above or below the zero-line, mainly because the indicator points to the position of the stock’s short-term average relative to its long-term measure. A MACD -a reading above the zero line means that the short-term is above the long-term average. This scenario implies that there is an upward momentum. The opposite is true when the MACD falls below the zero-line.
Analysts at JP Morgan raised their recommendation for DBD from Underweight to Neutral in May 11 review while maintain their target price of $6 to $7. JP Morgan analysts downgraded their recommendation of the stock from Neutral to Underweight while keeping its target price at $6 in a flash note released to investors on March 27. JP Morgan seeing the improvements upgraded the stock from Underweight to Neutral on November 01, placing it at $7.
The average rating for the DBD equity is 2.25 and is currently gathering a bullish momentum. Of 4 analysts tracking Diebold Nixdorf, Incorporated polled by Reuters, 2 rated DBD as a hold. The remaining 2 analysts were split evenly. However, the split wasn’t equal as a majority (2) rated it as a buy or strong buy. 0 analyst advised investors against buying the stock or to sell if they own any of the stock.
Elsewhere, the DBD stock price is 4.56X ahead of its 12-month Consensus earnings per share estimates.